GlassScriptPhysician profile
Jenny Daci Yang
NPI 1700021987
$10,348.54
in general payments reported to CMS, 2019-2025
14 companies · $410 in 2025
The $410 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,685 · 2020: $2,953 · 2021: $2,620 · 2022: $250 · 2023: $289 · 2024: $142 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,860.04 | 2019-2024 | |
| Abbvie INC. | $775.03 | 2019-2025 | Mavyret, Rinvoq |
| 3-D Matrix, INC. | $235.42 | 2025 | |
| Braintree Laboratories, INC. | $150.12 | 2019-2025 | Sutab, Suflave |
| Shionogi INC | $105.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.17 | 2021-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $30.94 | 2020 | |
| Alfasigma USA, INC. | $23.13 | 2020 | |
| Janssen Biotech, INC. | $22.36 | 2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $21.29 | 2019 | |
| Pfizer INC. | $18.84 | 2025 | |
| Madrigal Pharmaceuticals | $18.80 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $14.07 | 2021 | |
| Edwards Lifesciences Corporation | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.